Belite Bio Inc (BLTE)
BLTE trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026.
Profile
| Field | Value |
|---|---|
| Ticker | BLTE on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2022 |
| SEC CIK | 0001889109 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Cayman Islands |
Financials
Not reported in SEC XBRL data.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 20-F 2026-03-31 |
| Cash and burn | $352.9M cash; operating cash flow -$9.2M a quarter. | Report 2025-12-31 |
| Shares outstanding | 39,339,960 (2025-12-31); 31,826,549 a year earlier; 24,898,908 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2025-12-02 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Deloitte & Touche, Taipei, Taiwan | PCAOB Form AP 2026-04-18 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $40.5M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | Not filed | -$77.6M | -$37.0M | $352.9M | No debt tags | Needs four quarters | 20-F 2026-03-31 |
| FY 2024 2024-12-31 | Not filed | -$36.1M | -$29.2M | $31.7M | No debt tags | Needs four quarters | 20-F 2026-03-31 |
| FY 2023 2023-12-31 | Not filed | -$31.6M | -$29.8M | $88.2M | No debt tags | Needs four quarters | 20-F 2026-03-31 |
| FY 2022 2022-12-31 | Not filed | -$12.6M | -$11.5M | $42.1M | No debt tags | Needs four quarters | 20-F 2025-03-17 |
| FY 2021 2021-12-31 | Not filed | -$9.7M | -$7.5M | $17.3M | No debt tags | Needs four quarters | 20-F 2024-03-12 |
| FY 2020 2020-12-31 | Not filed | -$5.8M | -$4.4M | $25.6M | No debt tags | Needs four quarters | 20-F 2023-03-31 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2025-12-02 |
| Latest annual report | 20-F | 2026-03-31 |
| Latest quarterly / interim FORM 6-K | 6-K | 2026-11-12 |
Source: SEC EDGAR submissions feed, 216 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +6.6% |
| 1 month | +8.2% |
| 3 months | -1.2% |
| Year to date | +2.7% |
| 1 year | +46.2% |
| From 52-week high | -15.1% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ARWR | Arrowhead Pharmaceuticals Inc. | $44.21 | -7.47% | $6.2B |
| LGND | Ligand Pharmaceuticals Incorporated | $301.71 | -2.29% | $6.0B |
| GRFS | Grifols S.A. | $8.73 | +0.46% | $6.0B |
| SUPN | Supernus Inc. | $28.83 | -2.99% | $6.0B |
| MIRM | Mirum Pharmaceuticals Inc. | $91.58 | -2.56% | $6.0B |
| AXSM | Axsome Therapeutics Inc. | $137.01 | -3.30% | $7.2B |
| ABVX | Abivax SA | $83.61 | -4.53% | $7.3B |
| AMRX | Amneal Pharmaceuticals Inc. | $21.23 | -0.70% | $7.4B |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier